Our offerings under Regulation D Rule 506(c) are available to accredited investors only.
GENERALLY, NO SALE MAY BE MADE TO YOU IN THIS OFFERING IF THE AGGREGATE PURCHASE PRICE YOU PAY IS MORE THAN 10% OF THE GREATER OF YOUR ANNUAL INCOME OR NET WORTH. DIFFERENT RULES APPLY TO ACCREDITED INVESTORS AND NON-NATURAL PERSONS. BEFORE MAKING ANY REPRESENTATION THAT YOUR INVESTMENT DOES NOT EXCEED APPLICABLE THRESHOLDS, WE ENCOURAGE YOU TO REVIEW RULE 251(D)(2)(I)(C) OF REGULATION A. FOR GENERAL INFORMATION ON INVESTING, WE ENCOURAGE YOU TO REFER TO WWW.INVESTOR.GOV

Entrepreneurship and Medicine – David C. Karli

Cellular therapies are subject to federal regulations just like any other medical industry. Unfortunately development of many products have not been in compliance with FDA regulations and the Public Safety has not been assured in those situations. In this post Dr. Karli will go over the general landscape for responsible development and rules and regulations that are expected of practitioners and industry developers of cell therapy products.

Get in contact with David C. Karli through his website, LinkedIn and learn more about Greyledge Technologies here:

davidkarli.com

https://www.linkedin.com/in/davidkarli/

https://www.greyledgebiotech.com/

(Visited 1 times, 1 visits today)